Skip to content
Search

Latest Stories

Pharmacies losing thousands of pounds monthly on NHS prescriptions - NPA analysis reveals

Pharmacies losing thousands of pounds monthly on NHS prescriptions - NPA analysis reveals

NHS funding falls way short of the price local pharmacies have to pay for many common medicines

The National Pharmacy Association (NPA) has raised the alarm that many community pharmacies are facing losses on NHS prescriptions due to the “broken” funding system.

An analysis of prescription drug prices by the NPA revealed that pharmacies are being underpaid by the NHS by up to £75 a pack for common medicines, resulting in losses of thousands of pounds each month.


The analysis report released today (16 October) shows the government reimburses £18.06 for a 56-tablet pack of Amantadine, a drug used to treat Parkinson’s symptoms.

However, the market price of the drug is £94.05 per pack, leading to a loss of £75.99 per 56-tablet pack for pharmacies—amounting to a shortfall of over £1 per tablet.

In some instances, NHS funding covers only one-fifth of the cost that pharmacies have to pay for medicines, according to new figures from the NPA.

A survey of small independent community pharmacies also found that 85 per cent often make a net loss on NHS prescribing.

Paul Rees, CEO of the NPA said: “It is nothing short of a national scandal that pharmacies have to dig deep into their own pockets just to cover the cost of basic medicines that they dispense to patients in need of treatment. No other health professional would be asked to subsidise a key NHS service.”

He stated that the funding system for medicines, which millions of patients rely on, is “utterly broken.”

Furthermore, Rees stated that the government's ambitions to expand the role of pharmacies, which they share, “cannot happen whilst they are being forced to closing at record numbers by chronic underfunding.”

“The government must step in now to halt pharmacy closures, fix the broken funding system and deliver a new deal for pharmacies which will end the terrible toll of closures and cuts to services,” he added.

A national NHS Drug Tariff, funded by the Department of Health, is designed to cover the costs of medicines purchased by local pharmacies from suppliers.

However, an analysis by the NPA of the difference between wholesale medicine costs and NHS funding rates found that government funding falls way short of the price local pharmacies have to pay for many common medicines.

A snapshot of prices carried out on 7 October also found that:

Pharmacies are paid £1.72 to dispense a pack of Escitalopram, a common anti-depressant, but it costs them £9.08 to buy from suppliers – more than five times the amount they are reimbursed by the government.  A pharmacy would lose £7.59 per pack they dispense to a patient.

  •  Pharmacies are paid £3.16 to dispense Lorazepam, an anti-anxiety medication. However, it costs them £10.75 to buy in from a supplier, around 3.5 times more than this. A pharmacy would lose £7.59 per pack they dispense to a patient.
  •  Etoricoxib, an anti-inflammatory drug to treat conditions such as rheumatoid arthritis, costs pharmacies £19.47 to buy from their supplier per pack. However, they receive £6.75 from the NHS to dispense the medication, a third of the cost. A pharmacy would lose £12.72 per pack they dispense to a patient.

An NPA survey conducted earlier this year showed that many existing pharmacies have been compelled to take drastic measures to stay open, with 64 per cent of independent pharmacy owners stating that they have borrowed money from family and friends or used their savings due to financial pressures.

The association, which represents independent community pharmacies in the UK, highlighted that chronic underfunding was placing intolerable financial pressure on pharmacies, leading to the closure of more than 1,500 in the past decade.

NHS funding accounts for 90 per cent of an average community pharmacy’s income, but it has fallen by 40 per cent real terms cuts since 2017, the NPA stated.

Recently, the NPA launched its first-ever ballot of its members in over 100 years, asking whether they should implement collective 'work to rule' measures if their funding situation does not improve.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less